Sugi Predict

Sugi Predict / Compounds / Lobendazole

Lobendazole

Lobendazole

SCHEMBL205437

CCOC(=O)Nc1nc2ccccc2[nH]1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.64
▸ NPC1 O15118 7/20 0.60
▸ RAB9A P51151 7/20 0.60
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ ALDH1A1 P00352 3/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ PKM P14618 3/20 0.59
▸ KLF5 Q13887 2/20 0.59
▸ OPRK1 P41145 1/20 0.59
▸ SPHK2 Q9NRA0 1/20 0.59
▸ SPHK1 Q9NYA1 1/20 0.59
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ POLB P06746 2/20 0.58
▸ HTT P42858 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ HSD17B10 Q99714 3/20 0.57
▸ MAOB P27338 1/20 0.57
▸ ADORA2A P29274 1/20 0.57
▸ MAPK1 P28482 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lobendazole SCHEMBL29682294 1.00 LMNA (0.64) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL27493371 0.89 LMNA (0.58) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11868109 0.89 TUBB4A (0.65) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL30084551 0.87 LMNA (0.56) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL22401 0.87 LMNA (0.56) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11865449 0.87 NPC1 (0.65) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
Carbendazim SCHEMBL29357746 0.85 LMNA (0.71) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
Carbendazim SCHEMBL8427009 0.85 LMNA (0.71) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
Carbendazim SCHEMBL21051 0.85 LMNA (0.71) LMNANPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11806582 0.85 LMNA (0.59) LMNANPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210063375-A1 SCREENING AND CONFIRMATION METHOD FOR VETERINARY DRUGS AND ADDITIVES IN ANIMAL-DERIVED FOOD HENAN INST OF VETERINARY DRUG AND FEED CONTROL (CN) 2021-03-04 — — US claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 — — EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 — — WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 — — US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 — — CN claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US claimed
US-8062870-B2 Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs XENOPORT, INC. (US) 2011-11-22 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XENOPORT, INC. 2005-10-27 — — US claimed
US-6927036-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XERO PORT, INC. (US) 2005-08-09 — — US claimed
EP-1363625-A4 COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS COMBINATORX INC (US) 2004-07-14 — — EP claimed
WO-2004006849-A2 COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 — — WO claimed
EP-1363625-A1 COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS Combinatorx, Incorporated (US) 2003-11-26 — — EP claimed
US-20020165261-A1 Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders ZALICUS INC. 2002-11-07 — — US claimed
WO-2002058697-A1 COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS COMBINATORX, INCORPORATED (US) 2002-08-01 — — WO claimed
US-5684018-A Acyloxyisopropyl carbamates as prodrugs for amine drugs MERCK & CO., INC. (US) 1997-11-04 — — US claimed
WO-1996018605-A1 ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS MERCK & CO., INC. (US) 1996-06-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165261-A1 Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders DHFR, DPYD, VHL LMNA 2776/4885NPC1 2404/4885RAB9A 3865/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA LMNA 2248/4885NPC1 739/4885RAB9A 2254/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA LMNA 2248/4885NPC1 739/4885RAB9A 2254/4885
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof AADAC, UGT1A1, ABHD5 LMNA 2708/4885NPC1 429/4885RAB9A 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.